The objective for human gene therapy is to express exogenous DNA at a site
in vivo for long enough, and at sufficient levels to produce a therapeutic
response. The obstacles to this objective are numerous and include the form
ulation or packaging of the DNA, in vivo delivery, penetration of biologica
l. barriers, DNA elimination within the cell and from the tissue compartmen
ts of the whole body, control of product expression and overt toxicity. The
current challenge is to resolve each of these obstacles to produce a pract
ical and efficient gene therapy. In doing so, it is vital to understand the
disposition of DNA vectors in vivo, and to know how conventional medicines
may be used to modulate this disposition and to enhance the therapeutic ef
fect of these vectors. Many of the general concepts of human gene therapy h
ave been reviewed extensively in the literature. This review discusses some
of the pharmacological aspects of gene delivery and the fate of vectors in
vivo, and then highlights how drugs are being used to modulate gene therap
y.